Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
Bridge the gap between data complexity and operational efficiency
IQVIA eCOA delivers unparalleled data quality, integrity and patient compliance to optimize your data collection. Experience an eCOA platform that provides accelerated pathways to market with transformative decisions fueled by real-time insights.
IQVIA eCOA captures data in real time to accelerate decision-making.
Our eCOA solution does all the heavy lifting to ensure your primary endpoints are achieved. With real-time data capture, autogenerated regulatory and project documentation and streamlined workflows, IQVIA eCOA will help you reduce implementation timelines by up to 75%.
An eCOA solution designed for you, built for your patients.
IQVIA eCOA is purpose-built to support the evolving demands of modern clinical research, combining scientific credibility, global scalability and advanced digital innovation. Our eCOA solution enables confident decision-making by delivering high-quality, regulatory-ready data through a seamless and patient-centric experience. With deep therapeutic expertise and a proven global footprint, IQVIA eCOA accelerates study timelines, enhances data integrity and ensures operational excellence across every phase of your trial. Explore how below:
Diary Creation
Intuitive eCOA design at your fingertips with IQVIA Sculptor
IQVIA Sculptor simplifies the diary creation process for sponsors by offering a highly visual, drag-and-drop interface that streamlines the design of eCOA instruments. Instead of relying on complex programming, lengthy specification documents and lots of back and forth with designers, sponsors can quickly build, customize and preview patient diaries in real time. Sculptor ensures consistency with regulatory and protocol requirements while reducing development timelines and minimizing costly rework.
Its collaborative features also allow cross-functional teams to review and iterate on content within a single platform, enhancing transparency and accelerating study startup. By making diary creation more intuitive and efficient, Sculptor empowers sponsors to focus on study outcomes rather than technical hurdles.
The IQVIA Scribe App: Designed for the patient experience
The IQVIA eCOA solution is designed with a strong emphasis on patient-centricity, and the patient facing IQVIA Scribe app exemplifies this approach. Scribe streamlines the data collection process by offering an intuitive, user-friendly interface that empowers patients to easily report their health outcomes in real time, no matter what they’re doing. The app supports multiple languages and accessibility features, ensuring inclusivity across multiple patient populations. By minimizing technical barriers and integrating seamlessly with patients’ daily routines, Scribe enhances engagement and compliance, ultimately improving data quality and the overall clinical trial experience. Its offline capabilities and secure data handling further reinforce trust and convenience, making it a vital tool in modern, patient-focused research.
Blog
IQVIA wins the Fierce CRO Award for Innovative Approaches to Patient-Centric Research
IQVIA has been honored with the Fierce CRO Award for its work in patient-centric research. By integrating innovative technologies and deeply understanding patient needs, IQVIA is redefining how clinical trials are designed and executed. This approach prioritizes accessibility, engagement and real-world relevance, ensuring that patients are active partners in the research journey. This recognition underscores IQVIA’s leadership in shaping a more inclusive and effective future for clinical development. Read more about the award, what winning means to IQVIA and where our patient focused products are going in the future in this blog.
Efficiency Meets Scale: The Power of the IQVIA eCOA Library
The IQVIA eCOA Library is a powerful resource designed to accelerate study startup and reduce complexity for sponsors by providing access to a curated collection of pre-validated, protocol-ready eCOA instruments. With standardized formats and proven configurations, sponsors can quickly identify and deploy the right assessments for their trials, minimizing customization and reducing time spent on design and validation. The library supports regulatory compliance and global scalability, ensuring consistency across studies while maintaining flexibility for specific therapeutic areas. By leveraging the eCOA Library, sponsors gain a faster, more efficient path to high-quality data collection and improved patient engagement.
Case study
Custom eCOA library reduces oncology program timelines by 50%
Discover how a large oncology sponsor created a customized eCOA library to collect accurate, daily reported patient data across 13 countries. There was no room for error to ensure each input could ladder up into one resolution.
IQVIA eCOA enabled the sponsor to create eight new COA instruments, manage 27 languages and obtain all the necessary validations and licenses to accelerate the successful outcome of this vital oncology trial.
IQVIA eCOA: Driving Unmatched Patient Compliance Through Smart, Inclusive Technology
The IQVIA eCOA solution delivers industry-leading compliance rates, up to 95% in studies using automated data monitoring, by combining intuitive design, real-time data capture and inclusive technology. Patients can use their own devices or provisioned ones, with support for online and offline reporting, caregiver input and accessibility features like larger screens and fonts. Automated prompts and alerts keep participants engaged, while centralized updates ensure seamless mid-study changes. With the highest compliance rates and the broadest support for diverse populations, IQVIA eCOA empowers sponsors to collect cleaner data, reduce missing entries and enhance trial outcomes.
Ensuring your BYOD strategy meets the rigor of regulators
Can patients reliably complete eCOAs on their own devices?
In today’s patient-centric trials, eCOAs empower participants to share their experiences from anywhere—no clinic visit required. But as sponsors explore Bring Your Own Device (BYOD) strategies to reduce burden and boost compliance, one question looms large: will regulators approve it? Discover how IQVIA helps sponsors navigate BYOD implementation with confidence, ensuring data quality, regulatory readiness and a seamless patient experience.
Turning Up the Volume on Patient Voice in Clinical Trials
IQVIA’s eCOA platform is designed to elevate the patient experience by making it easier, more intuitive and more inclusive for participants to share their treatment journeys. With secure, user-friendly apps that work across personal and provisioned devices, whether online or offline, patients can report outcomes anytime, anywhere. Automated prompts and alerts help ensure assessments are completed on time, while accessibility features like larger fonts and caregiver login options support diverse needs. By enabling real-time, high-quality data collection directly from the patient, IQVIA eCOA ensures that every voice is heard, every experience is captured and every insight drives better trial outcomes.
Tailored solutions
For patient populations requiring caregiver reporting or assistance, IQVIA eCOA offers caregiver login functionality.
IQVIA eCOA partners with IQVIA’s Patient Centered Solutions team to ensure that the clinical outcome assessment strategy aligns with targeted patient population and study objectives.
For patients experiencing vision impairment, IQVIA eCOA provides bigger screens and tablets with larger font sizes.
Easy-to-use-app
Preprogrammed logic and edit checks help patients navigate questionnaires successfully.
Notifications and alerts prompt patients to complete eDiaries, improving compliance rates.
Bring your own device
IQVIA eCOA allows patients to securely use devices they already own, which reduces costs and patient burden while increasing patient compliance.
IQVIA eCOA provisions devices where needed, including iPad devices and other tablets if smaller devices are not ideal for some patients.
IQVIA eCOA provides device provisioning services that expand access to trial participation to socioeconomically and geographically diverse populations.
Backup devices are available if patients’ primary devices fail.
Patient compliance
IQVIA eCOA technology works seamlessly with patients’ daily routines to make capturing data and recording important experiences easy.
An intuitive user interface offers a consistent experience for patients whether they use it online or offline.
Compliance statistics help clinicians see how well patients are keeping up with reporting.
Robust training
Along with a show of appreciation, IQVIA eCOA supports trial participants with easy-to-follow training that also helps to mitigate technology hesitancy.
Therapeutic alignment
IQVIA eCOA configures each assessment experience to align with specific therapeutic-area requirements, including:
DISCOVER WHY PALVELLA THERAPEUTICS QUICKLY BENEFITED FROM DEPLOYING IQVIA eCOA
IQVIA and Palvella Therapeutics: Why IQVIA?
Overview: IQVIA accelerates performance excellence in obesity trials
IQVIA helped accelerate performance excellence in obesity trials by combining scientific expertise, digital technology, including eCOA solutions and end-to-end support. The platform achieved over 90% patient compliance, improved data quality by 50% and reduced setup timelines by up to 75%, enabling sponsors to run faster, more efficient, and regulator-ready studies.
In response to the rapidly growing obesity drug market, IQVIA delivered a comprehensive solution that streamlined trial execution and enhanced data integrity. By integrating scientific strategy, preapproved obesity assessments within eCOA and connected device support, IQVIA enabled sponsors to design and implement trials with speed and precision. The platform’s automation features, such as real-time alerts triggered by glucometer readings, minimized patient burden and ensured timely, accurate data capture. IQVIA’s agile ecosystem supported adaptive trial designs and faster database lock timelines, driving deeper insights and proactive decision-making. Over the past five years, IQVIA has supported more than 80 obesity trials across 45 countries, enrolling over 60,000 patients. The result: a one-stop shop for high-performance, compliant obesity trials that deliver measurable impact.
Challenge
Challenge: Navigating Complexity in a Rapidly Growing Obesity Market
With the global obesity drug market surpassing $30 billion in 2024, sponsors face mounting pressure to run fast, efficient and regulator-ready trials. They must navigate complex trial designs, ensure high-quality data collection through eCOAs and adapt quickly to protocol changes—all while maintaining scientific rigor and compliance.
The obesity drug market is expanding rapidly, creating intense demand for clinical trials that are both scientifically sound and operationally agile. Sponsors must manage multifaceted challenges, including designing effective trial strategies, selecting appropriate outcome assessments and ensuring data accuracy and timeliness. eCOAs play a critical role, but they must be flexible enough to accommodate protocol changes and deliver regulator-ready data. Speed and innovation are essential, as sponsors strive to differentiate their products and meet evolving regulatory expectations. The complexity of obesity trials—often involving comorbidities and diverse endpoints—requires a strategic, integrated approach to trial design and execution. IQVIA’s solution addresses these needs by combining scientific expertise, digital technology and end-to-end support to streamline the entire trial lifecycle.
Solution
End-to-End Innovation for Smarter Obesity Trial Execution
IQVIA delivered an integrated, end-to-end solution for obesity trials, combining scientific strategy, eCOA technology and connected device support. Their agile platform accelerated setup timelines by up to 75%, improved data quality by 50% and achieved over 90% patient compliance—ensuring trials were efficient, compliant and regulator-ready.
IQVIA’s solution brought together scientific expertise, digital innovation and operational support to streamline obesity trial execution. Their team of seasoned advisors guided sponsors through endpoint strategy, instrument selection and regulatory alignment, ensuring scientifically sound and compliant trial designs. The eCOA platform was built with agility in mind, enabling rapid setup and seamless integration with connected devices like glucometers, which automatically triggered relevant assessments based on patient data. IQVIA’s preapproved library of obesity-related assessments further accelerated study builds. The platform’s automation and real-time monitoring capabilities reduced patient burden, improved data accuracy and supported adaptive trial designs. With over 80 obesity trials supported across 45 countries, IQVIA’s comprehensive approach delivered measurable improvements in trial performance and data quality.
Results
Driving Performance Excellence in Obesity Research
IQVIA’s comprehensive solution delivered measurable impact across obesity trials, achieving over 90% patient compliance and improving data quality by 50%. Their agile platform expedited COA strategies by up to 40% and reduced eCOA setup timelines by as much as 75%, supporting faster, more efficient trial execution.
IQVIA’s eCOA platform significantly enhanced trial performance in obesity studies, achieving over 90% patient compliance with diaries and improving data quality by 50%. The solution accelerated COA measurement strategies by up to 40% and reduced eCOA setup timelines by up to 75%, enabling faster trial starts and more efficient execution. Integrated connected devices, such as glucometers, automatically triggered relevant assessments based on patient data, reducing manual entry and ensuring timely event capture. An automated dashboard monitored trends and risks, allowing for proactive issue resolution. The platform’s agility supported adaptive trial designs and faster database lock timelines, streamlining final endpoint analysis. Over the past five years, IQVIA has supported more than 80 obesity trials across 45 countries, enrolling over 60,000 patients at more than 2,000 sites.